← Leaderboards
Richard Bruce Roden
Johns Hopkins University
$11,133,737
Attributed
$14,432,343
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,432,343 · 14
By mechanism
R01$7,287,347 · 3
P50$5,774,234 · 7
RC2$999,578 · 1
P30$193,482 · 1
R21$177,702 · 1
P01$0 · 1
Top collaborators
- Warner King Huh11 shared
- Robert L Garcea6 shared
- Chien-Fu Hung5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Robert J. Kurman$1,242,232
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusBaseMalignant Neoplasm Of Cervix UteriMalignant NeoplasmsVaccinationVaccinesAntigensInfectionAntibodiesNeutralizing AntibodyHuman Papillomavirus 16Human Papilloma Virus InfectionProgramsPreventWomanVirus-Like ParticleHuman Papilloma Virus VaccinePreventiveVirusCostViralVaccinatedOncogenicProteins
Grant awards (56)
A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGridTM Electroporation$367,205
P50 · FY2025 · CA · contact PI
Thermostable RG-1 VLPs, A Candidate Broadly Protective HPV Vaccine for the Prevention of Cervical Cancer Globally$236,929
P50 · FY2025 · CA · contact PI
A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGridTM Electroporation$322,209
P50 · FY2024 · CA · contact PI
Thermostable RG-1 VLPs, A Candidate Broadly Protective HPV Vaccine for the Prevention of Cervical Cancer Globally$228,702
P50 · FY2024 · CA · contact PI
Mouse modeling of HPV infection$581,637
R01 · FY2023 · CA
Mouse modeling of HPV infection$582,604
R01 · FY2022 · CA
Mouse modeling of HPV infection$595,447
R01 · FY2021 · CA
Cancer Prevention and Control Program - 05$36,923
P30 · FY2021 · CA · contact PI
Mouse modeling of HPV infection$596,384
R01 · FY2020 · CA
Cancer Prevention and Control Program - 05$36,923
P30 · FY2020 · CA · contact PI
Mouse modeling of HPV infection$596,869
R01 · FY2019 · CA
Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer$300,583
P50 · FY2019 · CA · contact PI
Cancer Prevention and Control Program - 05$36,923
P30 · FY2019 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$291,600
R01 · FY2018 · CA · contact PI
Local TA-CIN/GPI-0100 Vaccination and Imiquimod for Persistent HPV16+/Normal Cytology Patients$252,218
P50 · FY2018 · CA · contact PI
Cancer Prevention and Control Program - 05$36,914
P30 · FY2018 · CA · contact PI
Cancer Prevention and Control Program - 05$6,863
P30 · FY2018 · CA · contact PI
Cancer Prevention and Control Program - 05$2,068
P30 · FY2018 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$291,600
R01 · FY2017 · CA · contact PI
Local TA-CIN/GPI-0100 Vaccination and Imiquimod for Persistent HPV16+/Normal Cytology Patients$257,782
P50 · FY2017 · CA · contact PI
Cancer Prevention and Control Program - 05$36,868
P30 · FY2017 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$291,600
R01 · FY2016 · CA · contact PI
Local TA-CIN/GPI-0100 Vaccination and Imiquimod for Persistent HPV16+/Normal Cytology Patients$241,270
P50 · FY2016 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$291,600
R01 · FY2015 · CA · contact PI
Local TA-CIN/GPI-0100 Vaccination and Imiquimod for Persistent HPV16+/Normal Cytology Patients$243,724
P50 · FY2015 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$291,600
R01 · FY2014 · CA · contact PI
Local TA-CIN/GPI-0100 Vaccination and Imiquimod for Persistent HPV16+/Normal Cytology Patients$241,078
P50 · FY2014 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$303,911
P50 · FY2013 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$247,234
P50 · FY2013 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$111,720
P50 · FY2013 · CA
L1 capsomeres as a next generation preventive HPV vaccine$325,893
P50 · FY2012 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$264,933
P50 · FY2012 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$319,954
P50 · FY2011 · CA
Mechanisms of Papillomavirus Neutralization$272,027
R01 · FY2011 · CA · contact PI
Development of a Pan-Oncogenic HPV Preventive Vaccine$262,026
P50 · FY2011 · CA · contact PI
Development of low cost and broadly protective human papillomavirus vaccines$499,580
RC2 · FY2010 · CA · contact PI
L1 capsomeres as a next generation preventive HPV vaccine$310,410
P50 · FY2010 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$310,397
P50 · FY2010 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$280,440
R01 · FY2010 · CA · contact PI
Tumor-Associated Antigens in Early Stage Serous Carcinoma$263,559
R01 · FY2010 · CA · contact PI
Development of low cost and broadly protective human papillomavirus vaccines$499,998
RC2 · FY2009 · CA · contact PI
Ll capsomeres as a next generation preventive HPV vaccine$313,322
P50 · FY2009 · CA
Development of a Pan-Oncogenic HPV Preventive Vaccine$312,734
P50 · FY2009 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$280,440
R01 · FY2009 · CA · contact PI
Tumor-Associated Antigens in Early Stage Serous Carcinoma$258,389
R01 · FY2009 · CA · contact PI
Tumor-Associated Antigens in Early Stage Serous Carcinoma$304,849
R01 · FY2008 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$280,440
R01 · FY2008 · CA · contact PI
Tumor-Associated Antigens in Early Stage Serous Carcinoma$301,831
R01 · FY2007 · CA · contact PI
Mechanisms of Papillomavirus Neutralization$280,440
R01 · FY2007 · CA · contact PI
Tumor-Associated Antigens in Early Stage Serous Carcinoma$353,991
R01 · FY2006 · CA · contact PI
DEVELOPMENT OF PAN-ONCOGENIC HPV PREVENTIVE VACCINE$0
P50 · FY2003 · CA
AUTOLOGOUS ANTIBODY FOR OVARIAN CANCER SCREENING$14,202
R21 · FY2002 · CA
Humoral immune responses for Human Papillomavirus vaccine trials$0
P01 · FY2002 · AI
AUTOLOGOUS ANTIBODY FOR OVARIAN CANCER SCREENING$163,500
R21 · FY2001 · CA
Humoral immune responses for Human Papillomavirus vaccine trials$0
P01 · FY2001 · AI
Humoral immune responses for Human Papillomavirus vaccine trials$0
P01 · FY2000 · AI